Zonisamide

Generic Name
Zonisamide
Brand Names
Zonegran, Zonisade, Zonisamide Mylan
Drug Type
Small Molecule
Chemical Formula
C8H8N2O3S
CAS Number
68291-97-4
Unique Ingredient Identifier
459384H98V
Background

Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory...

Indication

Zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Zonisamide oral suspension is indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years of age and older.

Associated Conditions
Partial-Onset Seizures
Associated Therapies
-
Clinical Trials
Related News

Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse

First Posted Date
2010-06-07
Last Posted Date
2017-09-05
Lead Sponsor
Johns Hopkins University
Target Recruit Count
19
Registration Number
NCT01137890
Locations
🇺🇸

Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States

A Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Extension Study)

Phase 3
Completed
Conditions
Partial Seizures
Interventions
Drug: Zonisamide
First Posted Date
2010-06-04
Last Posted Date
2016-01-25
Lead Sponsor
Eisai Limited
Target Recruit Count
144
Registration Number
NCT01136954

Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation

Phase 4
Completed
Conditions
Epilepsy
Interventions
Drug: zonisamide
Drug: carbamazepine
First Posted Date
2010-05-20
Last Posted Date
2022-01-04
Lead Sponsor
Eisai Korea Inc.
Target Recruit Count
200
Registration Number
NCT01127256
Locations
🇰🇷

Seoul National Univ. Bundang Hosp., Bundang, Korea, Republic of

🇰🇷

Dongguk Univ. Ilsan Hosp., Ilsan, Korea, Republic of

🇰🇷

Boramae Medical Center, Seoul, Korea, Republic of

and more 9 locations

Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism

First Posted Date
2009-03-17
Last Posted Date
2015-04-28
Lead Sponsor
Boston Medical Center
Target Recruit Count
85
Registration Number
NCT00862563
Locations
🇺🇸

Boston University School of Medicine, Boston, Massachusetts, United States

Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures

Phase 3
Completed
Conditions
Epilepsy
Interventions
Drug: Zonisamide
Drug: Carbamazepine
First Posted Date
2009-02-20
Last Posted Date
2015-12-24
Lead Sponsor
Eisai Inc.
Target Recruit Count
295
Registration Number
NCT00848549

Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine

Not Applicable
Withdrawn
Conditions
Migraine
Interventions
Drug: zonisamide
Drug: propranolol
Drug: topiramate
First Posted Date
2008-10-22
Last Posted Date
2020-12-17
Lead Sponsor
University of South Alabama
Registration Number
NCT00777218
Locations
🇺🇸

University of South Alabama Department of Neurology, Mobile, Alabama, United States

Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate

Phase 4
Completed
Conditions
Epilepsy
Interventions
Drug: Zonisamide
Drug: Sodium valproate
First Posted Date
2008-07-11
Last Posted Date
2015-11-03
Lead Sponsor
Eisai Limited
Target Recruit Count
2
Registration Number
NCT00713622
Locations
🇫🇮

Kuopio University Hospital, Kuopio, Finland

🇦🇹

Universitae Klinik fur Neurologiet, Innsbruck, Austria

Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy

Phase 3
Terminated
Conditions
Epilepsy
Interventions
Drug: Placebo
Drug: Zonisamide
First Posted Date
2008-06-06
Last Posted Date
2015-12-24
Lead Sponsor
Eisai Limited
Target Recruit Count
10
Registration Number
NCT00693017
Locations
🇦🇺

Strategic Health Evaluators Pty Ltd, Chatswood, New South Wales, Australia

🇦🇺

The Prince of Wales Hospital, Randwick, New South Wales, Australia

🇭🇺

Vas County Markusovszky Hospital, Szombathely, Hungary

and more 68 locations

Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures

Phase 3
Terminated
Conditions
Epilepsy
Interventions
Drug: Zonisamide
Drug: Placebo
First Posted Date
2008-06-06
Last Posted Date
2017-03-14
Lead Sponsor
Eisai Limited
Target Recruit Count
21
Registration Number
NCT00692003
Locations
🇨🇿

Fakultni nemocnice Plzen, Plzen, Czech Republic

🇪🇪

West-Tallinn Central Hospital, Tallinn, Estonia

🇵🇱

Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Gdansk, Poland

and more 68 locations

ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs

Phase 4
Completed
Conditions
Epilepsy
Interventions
Drug: Zonisamide
First Posted Date
2008-04-17
Last Posted Date
2013-05-13
Lead Sponsor
Eisai Inc.
Target Recruit Count
32
Registration Number
NCT00659958
Locations
🇪🇸

Complejo Hospitalario de Pontevedra, Pontevedra, Galicia, Spain

🇪🇸

Complejo Hospitalario Universitario 'Juan Canalejo', Coruna, Galicia, Spain

🇪🇸

Centro Sanitario Complexo Hospitalario "XERAL-CALDE", Lugo, Galicia, Spain

and more 8 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy